Table 1 Baseline characteristics
Multi-center cohort data | Administrative cohort data | |||||
|---|---|---|---|---|---|---|
Variable | Overall (n = 153) | Early tapering group (n = 87) | Non-early tapering group (n = 66) | Overall (n = 229) | Early tapering group (n = 87) | Non-early tapering group (n = 142) |
Etiology of AE (idiopathic/ infection/ drug/ aspiration) | 130(85%)/ 16(10%)/ 6(4%)/ 1(1%) | 74(85%)/ 8(9%)/ 5(5%)/ 0(0%) | 56(85%)/ 8(12%)/ 1(2%)/ 1(2%) | NA | NA | NA |
Institution (A/ B/ C/ D/ E/ F/ G/ H) | 59(39%)/ 35(23%)/ 26(17%)/ 19(12%)/ 5(3%)/ 5(3%)/ 2(1%)/ 2(1%) | 44(51%)/ 7(8%)/ 21(24%)/ 7(8%)/ 3(3%)/ 3(3%)/ 2(2%)/ 0(0%) | 15(23%)/ 28(42%)/ 5(8%)/ 12(18%)/ 2(3%)/ 2(3%)/ 0(0%)/ 2(3%) | NA | NA | NA |
Age (years) | 78 (73–84) | 78 (71–82) | 78 (73–84) | 77 (71–82) | 78 (72–82) | 77 (70–82) |
Sex (male) | 113 (74%) | 70 (80%) | 43 (65%) | 160 (70%) | 68 (78%) | 92 (65%) |
KL-6 level (U/mL) | 1278 (780–2080) | 1262 (735–1950) | 1305 (811–2275) | 1118 (684–1814) | 1043 (676–1566) | 1152 (711–1873) |
Missing data | 18 (12%) | 7 (8%) | 11 (17%) | 49 (21%) | 14 (16%) | 35 (25%) |
LDH level (IU/L) | 344 (278–437) | 329 (263–405) | 374 (301–442) | 320 (260–389) | 320 (242–399) | 320 (267–389) |
Missing data | 2 (1%) | 2 (2%) | 0 (0%) | 12 (5%) | 5 (6%) | 7 (5%) |
CRP level (mg/dL) | 6.5 (3.2–11.6) | 6.6 (3.6–11.7) | 5.5 (2.6–10.3) | 4.8 (1.5–11.1) | 5.8 (1.6–11.8) | 4.4 (1.2–10.6) |
Missing data | 3 (2%) | 2 (2%) | 1 (2%) | 12 (5%) | 5 (6%) | 7 (5%) |
Albumin level (g/dL) | 3.1 (2.8–3.4) | 3.1 (2.7–3.5) | 3.1 (2.8–3.3) | 3.2 (2.9–3.5) | 3.1 (2.8–3.5) | 3.2 (2.9–3.5) |
Missing data | 4 (3%) | 3 (3%) | 1 (2%) | 16 (7%) | 6 (7%) | 10 (7%) |
PaO2/FiO2 | 186 (101–284) | 223 (90–295) | 178 (115–268) | NA | NA | NA |
Missing data | 37 (24%) | 27 (31%) | 10 (15%) | |||
CCI ( ≦ 2/3 or 4/≧5) | 116 (76%)/ 29 (19%)/8 (5%) | 63 (72%)/ 19 (22%)/ 5 (6%) | 53 (80%)/ 10 (15%)/ 3 (5%) | 76 (39%)/ 60 (30%)/ 61 (31%) | 29 (39%)/ 28 (38%)/ 17 (23%) | 47 (38%)/ 32 (26%)/ 44 (36%) |
Missing data | 0 (%) | 0 (%) | 0 (%) | 32 (14%) | 13 (15%) | 19 (13%) |
LDH level on day 7 (± 3) of admission (IU/L) | 306 (251–427) | 286 (219–369) | 350 (261–447) | 274 (218–344) | 267 (203–316) | 279 (225–361) |
Missing data | 7 (5%) | 5 (6%) | 2 (3%) | 43 (19%) | 28 (32%) | 15 (11%) |
CRP level on day 7 (± 3) of admission (mg/dL) | 1.3 (0.5–4.3) | 1.1 (0.4–2.7) | 2.1 (0.7–5.3) | 1.0 (0.3–3.2) | 1.0 (0.3–4.1) | 1.0 (0.3–3.2) |
Missing data | 6 (4%) | 4 (5%) | 2 (3%) | 40 (17%) | 28 (32%) | 12 (8%) |
Albumin level on day 7 (± 3) of admission (g/dL) | 2.7 (2.4–3.2) | 2.8 (2.5–3.2) | 2.7 (2.3–3.1) | 2.9 (2.5–3.2) | 2.8 (2.3-3.0) | 2.9 (2.6–3.2) |
Missing data | 29 (19%) | 18 (21%) | 11 (17%) | 72 (31%) | 37 (43%) | 35 (25%) |
SpO2/FiO2 on day 7 (± 3) of admission | 306 (207–400) | 323 (242–422) | 272 (160–392) | NA | NA | NA |
Missing data | 6 (4%) | 5 (6%) | 1 (2%) | |||
HRCT score | 260 (225–295) | 260 (220–305) | 270 (230–295) | NA | NA | NA |
Changes in Xp or CT findings on day7 (± 3) of admission (improve/stable/worsening) | 85 (59%)/ 39 (27%)/ 21 (14%) | 60 (74%)/15 (19%)/6 (7%) | 25 (39%)/24 (38%)/15 (23%) | NA | NA | NA |
Missing data | 8 (5%) | 6 (7%) | 2 (3%) | |||
Pre-admission treatment (No missing data) | ||||||
Oral steroid | 46 (30%) | 18 (21%) | 28 (42%) | 65 (28%) | 19 (22%) | 46 (32%) |
Immunosuppressant | 18 (12%) | 10 (11%) | 8 (12%) | 14 (6%) | 7 (8%) | 7 (5%) |
Pirfenidone | 12 (8%) | 8 (9%) | 4 (6%) | 25 (11%) | 9 (10%) | 16 (11%) |
Nintedanib | 13 (8%) | 6 (7%) | 7 (11%) | 4 (2%) | 2 (2%) | 2 (1%) |
Macrolide | 24 (16%) | 19 (22%) | 5 (8%) | 12 (5%) | 4 (5%) | 8 (6%) |
ST | 40 (26%) | 23 (26%) | 17 (26%) | 29 (13%) | 9 (10%) | 20 (14%) |
LTOT | 38 (25%) | 15 (17%) | 23 (35%) | NA | NA | NA |
In hospital mortality | 47 (31%) | 15 (17%) | 32 (48%) | 51 (22%) | 16 (18%) | 35 (25%) |